TrialMedicine2018

Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.

Giandomenico Roviello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.